However, ABL alternative splicing appears to be quite frequent in the normal population and an increase in expression levels and the frequency of these alternatively spliced BCR-ABL associated with imatinib resistance in the chronic phase of CML is still a matter of debate [77–79]. Here, BCR is linked to chronic myelogenous leukemia, BCR-ABL1 positive.